Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/60801 |
Resumo: | Ministério da Saúde (MS). Ministério da Ciência, Tecnologia e Inovação (MCTI). Secretaria de Ciência, Tecnologia, Inovação e Complexo da Saúde (SCTIE). Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Fundo Nacional de Desenvolvimento Científico e Tecnológico (FNDCT). |
id |
CRUZ_287b697b6a04444f80d9efad5a7e3944 |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/60801 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Cazé, Ana B.Silva, Thiago CerqueiraBomfim, Adriele P.Souza, Gisley L. deAzevedo, Amanda C. A.Brasil, Michelle Q. A.Santos, Nara R.Khouri, RicardoDan, JenniferBandeira, Antonio C.Cavalcanti, Luciano P. G.Barral Netto, ManoelBarral, AldinaBarbosa, Cynara G.Boaventura, Viviane S.2023-10-16T13:18:18Z2023-10-16T13:18:18Z2023CAZÉ, Ana B. et al. Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group. Journal of Global Health, v. 13, p. 1-9, 2023.2047-2986https://www.arca.fiocruz.br/handle/icict/6080110.7189/jogh.13.06015Ministério da Saúde (MS). Ministério da Ciência, Tecnologia e Inovação (MCTI). Secretaria de Ciência, Tecnologia, Inovação e Complexo da Saúde (SCTIE). Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Fundo Nacional de Desenvolvimento Científico e Tecnológico (FNDCT).Universidade Federal da Bahia. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Escola Baiana de Medicina e Saúde Pública. Salvador, BA, Brasil.Santa Casa da Bahia. Hospital Santa Izabel. Salvador, BA, Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Secretaria Municipal de Saúde. Departamento de Vigilância em Saúde e Vigilância Epidemiológica. Campo Formoso, BA Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Microbiology. Immunology and Transplantation. Rega Institute for Medical Research. Laboratory of Clinical and Epidemiological Virology. Belgium.Center for Infectious Disease and Vaccine Research. la Jolla Institute for Immunology. San Diego, California, USA / Department of Medicine. Division of Infectious Disease and Global Public Health. University of California. San Diego, California, USA.Faculdade de Tecnologia e Ciências de Salvador. Salvador, BA, Brasil / Laboratório Central do Estado Bahia. Salvador, BA, Brasil.Universidade Federal do Ceará. Fortaleza, CE, Brasil / Centro Universitário Christus. Fortaleza, CA, Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil /Instituto de Pesquisas em Imunologia. São Paulo. SP, Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Background: There is limited data on the prevalence and risk factors for long COVID and few prospective studies with appropriate control groups and adequate sample sizes. We performed a prospective study to determine the prevalence and risk factors for long COVID. Methods: We recruited individuals aged ≥15 years who were clinically suspected of having an acute SARS-CoV-2 infection from September 2020 to April 2021. We collected nasopharyngeal swabs three to five days following symptom onset for analysing using reverse transcriptase polymerase chain reaction (RT-PCR). We also collected clinical and sociodemographic characteristics from both SARS-CoV-2 positive and negative participants using structured questionnaires. We followed-up the participants via telephone interview to assess early outcomes and persistent symptoms. For COVID-19 cases, 5D-3L EuroQol questionnaire was used to assess the impact of symptoms on quality of life. Results: We followed 814 participants (412 COVID-19 positive and 402 COVID-19 negative persons). Most (n = 741/814) had mild symptoms. Both groups had similar sociodemographic and clinical characteristics, except for the hospitalization rate (15.8% in the COVID-19 positive vs 1.5% in the COVID-19 negative group). One month after disease onset, 122/412 (29.6%) individuals in the COVID-19 positive (long COVID) and 24 (6%) in the COVID-19 negative group reported residual symptoms. In the long COVID group, fatigue, olfactory disorder, and myalgia were the most frequent symptoms in the acute phase. Compared to recovered individuals, older age and having more than five symptoms during the acute phase were risk factors for long COVID. Quality of life was evaluated in 102 out of 122 cases of long COVID, with 57 (55.9%) reporting an impact in at least one dimension of the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) questionnaire. Conclusions: In this prospective study consisting predominantly of individuals with mild disease, the persistence of symptoms after an acute respiratory illness was associated with a diagnosis of COVID-19. Polysymptomatic acute disease and older age were risk factors for long COVID.engInternational Society of Global HealthPrevalênciaFatores de riscoCOVID 19CoorteGrupo sintomáticoPrevalenceRisk factorsCOVID 19CohortSymptomatic groupPrevalênciaFatores de riscoCOVID 19Estudos de CoortesPrevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control groupinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/60801/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALCazé, Ana B. - Prevalence and risk factors for long COVID after mild disease.pdfCazé, Ana B. - Prevalence and risk factors for long COVID after mild disease.pdfapplication/pdf867151https://www.arca.fiocruz.br/bitstream/icict/60801/2/Caz%c3%a9%2c%20Ana%20B.%20-%20Prevalence%20and%20risk%20factors%20for%20long%20COVID%20after%20mild%20disease.pdf31153f5c1d4f5247417b4b9a5c027d18MD52icict/608012023-10-16 10:18:19.149oai:www.arca.fiocruz.br:icict/60801Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-10-16T13:18:19Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.en_US.fl_str_mv |
Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group |
title |
Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group |
spellingShingle |
Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group Cazé, Ana B. Prevalência Fatores de risco COVID 19 Coorte Grupo sintomático Prevalence Risk factors COVID 19 Cohort Symptomatic group Prevalência Fatores de risco COVID 19 Estudos de Coortes |
title_short |
Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group |
title_full |
Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group |
title_fullStr |
Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group |
title_full_unstemmed |
Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group |
title_sort |
Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group |
author |
Cazé, Ana B. |
author_facet |
Cazé, Ana B. Silva, Thiago Cerqueira Bomfim, Adriele P. Souza, Gisley L. de Azevedo, Amanda C. A. Brasil, Michelle Q. A. Santos, Nara R. Khouri, Ricardo Dan, Jennifer Bandeira, Antonio C. Cavalcanti, Luciano P. G. Barral Netto, Manoel Barral, Aldina Barbosa, Cynara G. Boaventura, Viviane S. |
author_role |
author |
author2 |
Silva, Thiago Cerqueira Bomfim, Adriele P. Souza, Gisley L. de Azevedo, Amanda C. A. Brasil, Michelle Q. A. Santos, Nara R. Khouri, Ricardo Dan, Jennifer Bandeira, Antonio C. Cavalcanti, Luciano P. G. Barral Netto, Manoel Barral, Aldina Barbosa, Cynara G. Boaventura, Viviane S. |
author2_role |
author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Cazé, Ana B. Silva, Thiago Cerqueira Bomfim, Adriele P. Souza, Gisley L. de Azevedo, Amanda C. A. Brasil, Michelle Q. A. Santos, Nara R. Khouri, Ricardo Dan, Jennifer Bandeira, Antonio C. Cavalcanti, Luciano P. G. Barral Netto, Manoel Barral, Aldina Barbosa, Cynara G. Boaventura, Viviane S. |
dc.subject.other.en_US.fl_str_mv |
Prevalência Fatores de risco COVID 19 Coorte Grupo sintomático |
topic |
Prevalência Fatores de risco COVID 19 Coorte Grupo sintomático Prevalence Risk factors COVID 19 Cohort Symptomatic group Prevalência Fatores de risco COVID 19 Estudos de Coortes |
dc.subject.en.en_US.fl_str_mv |
Prevalence Risk factors COVID 19 Cohort Symptomatic group |
dc.subject.decs.en_US.fl_str_mv |
Prevalência Fatores de risco COVID 19 Estudos de Coortes |
description |
Ministério da Saúde (MS). Ministério da Ciência, Tecnologia e Inovação (MCTI). Secretaria de Ciência, Tecnologia, Inovação e Complexo da Saúde (SCTIE). Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Fundo Nacional de Desenvolvimento Científico e Tecnológico (FNDCT). |
publishDate |
2023 |
dc.date.accessioned.fl_str_mv |
2023-10-16T13:18:18Z |
dc.date.available.fl_str_mv |
2023-10-16T13:18:18Z |
dc.date.issued.fl_str_mv |
2023 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
CAZÉ, Ana B. et al. Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group. Journal of Global Health, v. 13, p. 1-9, 2023. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/60801 |
dc.identifier.issn.en_US.fl_str_mv |
2047-2986 |
dc.identifier.doi.none.fl_str_mv |
10.7189/jogh.13.06015 |
identifier_str_mv |
CAZÉ, Ana B. et al. Prevalence and risk factors for long COVID after mild disease: a cohort study with a symptomatic control group. Journal of Global Health, v. 13, p. 1-9, 2023. 2047-2986 10.7189/jogh.13.06015 |
url |
https://www.arca.fiocruz.br/handle/icict/60801 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
International Society of Global Health |
publisher.none.fl_str_mv |
International Society of Global Health |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/60801/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/60801/2/Caz%c3%a9%2c%20Ana%20B.%20-%20Prevalence%20and%20risk%20factors%20for%20long%20COVID%20after%20mild%20disease.pdf |
bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 31153f5c1d4f5247417b4b9a5c027d18 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813008953853870080 |